Medical Glossary

AUC, or Area Under the Curve, is a pharmacokinetic measure that quantifies total drug exposure in the bloodstream over a defined period. It represents the integral of plasma concentration versus time and is used to compare bioavailability between different formulations, doses, or administration routes. In telehealth prescribing — including ZYNDIO's compounded therapies — AUC data from published trials helps providers estimate how much active drug reaches systemic circulation and how long it remains at therapeutic levels.

Bioavailability is the fraction of an administered dose of unchanged drug that reaches systemic circulation. By definition, intravenous administration has 100% bioavailability; other routes (oral, transdermal, intramuscular) have varying bioavailability based on absorption, first-pass metabolism, and other factors.

BPC-157 (Body Protection Compound-157) is a 15-amino-acid peptide derived from human gastric juice protein, marketed in the wellness and "research peptide" space for tissue healing. It is not FDA-approved and is not currently authorized for compounding for human use.

A compounded medication is one prepared by a licensed pharmacist for a specific patient, typically because the commercially manufactured product is unavailable, the patient cannot tolerate an inactive ingredient, or a non-standard dose is clinically required. Compounded preparations are not FDA-approved as finished drug products.

A GLP-1 receptor agonist is a medication that activates the glucagon-like peptide-1 receptor, mimicking the body's GLP-1 hormone. The class is FDA-approved for type 2 diabetes and chronic weight management, and includes semaglutide, liraglutide, dulaglutide, and exenatide.

A growth hormone secretagogue is a substance that stimulates the pituitary to release endogenous growth hormone. The category includes GHRH analogs (sermorelin, tesamorelin, CJC-1295) acting through the GHRH receptor, and GHRPs (ipamorelin, MK-677) acting through the ghrelin receptor pathway.

Half-life (t½) is the time required for the plasma concentration of a drug to decrease by 50%. Half-life determines dosing frequency, time to steady state, and time to drug clearance after discontinuation.

Liraglutide is a glucagon-like peptide-1 (GLP-1) receptor agonist administered once daily via subcutaneous injection. The FDA approved liraglutide under the brand name Victoza for type 2 diabetes management and under the brand name Saxenda for chronic weight management in adults with obesity or overweight with at least one weight-related comorbidity. It mimics the action of naturally occurring GLP-1, a hormone that regulates blood sugar and appetite by slowing gastric emptying, enhancing insulin secretion, and reducing glucagon release. Compounded liraglutide formulations, which may be available through telehealth pharmacies like ZYNDIO, are not FDA-approved drug products and are prepared by state-licensed compounding pharmacies pursuant to a valid prescription from a licensed provider.

Peptide therapy refers to the clinical or off-label use of short chains of amino acids (peptides) for various therapeutic purposes including growth hormone modulation, tissue healing, and metabolic effects. The clinical evidence base varies dramatically across specific peptides — from FDA-approved indications to research-only.

Prescription titration is the structured stepwise increase of a medication dose over time, used to manage tolerability while reaching a target therapeutic dose. Titration schedules are typically specified in the FDA-approved label and are particularly important for medications like GLP-1 agonists and TRT.

Protected Health Information (PHI) refers to any individually identifiable health information that is created, received, maintained, or transmitted by a covered entity or business associate under the Health Insurance Portability and Accountability Act (HIPAA). PHI includes 18 specific identifiers defined by the HIPAA Privacy Rule, ranging from names and Social Security numbers to prescription records and payment history. When you consult with a licensed provider through ZYNDIO's telehealth platform, discuss medical history, receive a prescription for compounded semaglutide or finasteride, or process payment information, all of that data qualifies as PHI and receives federal privacy protection. Understanding PHI matters because it defines what information healthcare entities must safeguard, how they can use or disclose it, and what rights you have to access and control your own health records.

Semaglutide is a glucagon-like peptide-1 (GLP-1) receptor agonist FDA-approved for type 2 diabetes (Ozempic, Rybelsus) and chronic weight management (Wegovy). It is administered as a once-weekly subcutaneous injection or as a daily oral tablet, and acts by slowing gastric emptying, increasing satiety signaling, and improving glucose-dependent insulin secretion.

Tirzepatide is a dual glucose-dependent insulinotropic polypeptide (GIP) and glucagon-like peptide-1 (GLP-1) receptor agonist administered by weekly subcutaneous injection. The FDA approved tirzepatide for type 2 diabetes management in 2022 under the brand name Mounjaro, and for chronic weight management in adults with obesity or overweight with weight-related comorbidities in 2023 under the brand name Zepbound. Compounded tirzepatide formulations, which are prepared by state-licensed compounding pharmacies pursuant to valid prescriptions, are not FDA-approved drug products and differ from the branded versions in formulation, dosing, and regulatory oversight.